Re: “early outpatient treatment of symptomatic, high-risk covid-19 patients that should be ramped up immediately as key to the pandemic crisis”

In his recently accepted manuscript on treatment of coronavirus disease 2019 (COVID-19), Dr. Harvey Risch criticizes the National Institutes of Health and the Food and Drug Administration because their reviews “have omitted the 2 critical aspects of reasoning about these drugs: use of HCQ [hydroxychloroquine] combined with AZ [azithromycin] or with DOX [doxycycline] and use in the outpatient setting” (1, p. 000).
Source: American Journal of Epidemiology - Category: Epidemiology Source Type: research